[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409719":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":29,"responsibleParty":51,"collaborators":24,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":32,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab","EXPERIMENTAL","Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w\\*2 cycles) and as adjuvant treatment after surgery for 1 year",[13],"Drug: Tislelizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Tislelizumab Combined Lenvatinib","Patients enrolled will receive Tislelizumab combined Lenvatinibas neoadjuvant treatment before surgery (Tislelizumab: 200mg q3w\\*2 cycles+Lenvatinib 8\u002F12mg qd\\*4weeks) and as adjuvant treatment after surgery for 1 year",[18],"Drug: Tislelizumab combined with Levatinib",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Tislelizumab combined with Levatinib","Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8\u002F12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The First Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510080","China","CN",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Ming Kuang, MD. PhD.","CONTACT","008687755766","8576","kuangm@mail.sysu.edu.cn",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Ming Kuang","Professor","100409719","phase-2-tislelizumab-or-tislelizumab-combined-with-lenvatinib-neo-adjuvant-treatment-for-resectable-rhcc-100409719",false,"NCT04615143","Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC","Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable Recurrent Hepatocellular Carcinoma：Phase II Non-randomized Control Clinical Trial","TALENT","Inclusion Criteria:\n\n1. Diagnosed as recurrent hepatocellular carcinoma after curative treatment;\n2. The criteria for resectability is met;\n3. Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment;\n4. Eastern Cooperative Oncology Group score 0-1, Child-pugh score 5-7;\n5. Agree to biopsy and blood sample collection;\n6. Adequate organ and marrow function.\n\nExclusion Criteria:\n\n1. Previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation;\n2. Extrahepatic metastasis;\n3. History of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding;\n4. History of autoimmune disease or need to take immunosuppressant drugs for a long time;\n5. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);\n6. Abnormal organ function","ALL","18 Years","75 Years",{"count":67,"type":68},80,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients",[74],"Recurrent Hepatocellular Carcinoma",[76,77,78],"recurrent hepatocellular carcinoma","neoadjuvant treatment","immune therapy","2025-01-07",{"date":81,"type":82},"2025-01-09","ACTUAL",{"date":84,"type":82},"2020-12-01",{"date":86,"type":68},"2027-12-01",{"name":5,"class":6},1]